All In Biotech

Drug Trial Radar · NCT02654171

Viral Inhibition in Children for Treatment of RSV

A Randomized, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered AK0529 to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Single and Multiple Dosing in Hospitalized Infants With Respiratory Syncytial Virus Infection

Last checked: Nov 20, 2026Latest source record: Feb 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

May 27, 2016

Primary completion

Mar 31, 2019

Study completion Apr 9, 2019

Sponsor

Sponsor type
Industry
Collaborators
Ark Biosciences Pty Ltd.
First posted
Jan 13, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 1 month, up to 24 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

VICTOR is a randomized, double-blind, placebo-controlled, multicenter, 2-part study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antiviral effect of single and multiple dosing of AK0529 in infants hospitalized with RSV infection.

Conditions

  • RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

Interventions

  • AK0529Drug

    AK0529 is a novel compound being developed for the treatment of RSV infection. The enteric coated drug pellets with sugar core can be administered orally with apple sauce/purée or yoghurt, or by flushing with 10% dextrose water via a nasogastric or other feeding tube, or upon a glucose wafer.

  • PlaceboDrug

    The placebo was made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed primarily of microcrystaline cellulose pellet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events during the studyTime frame: Day -4 to single dose Day 7 (Part 1) and Day -3 to multiple dose Day 14 (Part 2)
  2. Subject withdrawals due to Adverse EventsTime frame: Day -4 to single dose Day 7 (Part 1) and Day -3 to multiple dose Day 14 (Part 2)

Locations

28 sites in 8 countries. Site status is shown where the registry gives one.

  • Gold Coast University Hospital

    Gold Coast, Queensland, Australia

  • Lady Cilento Children's Hospital

    South Brisbane, Queensland, Australia

  • Women's and Children's Hospital

    Adelaide, South Australia, Australia

  • Prince of Wales Hospital

    Shatin, Hong Kong

  • Soroka University Medical Center

    Beersheba, Israel

  • Ruth Rappaport Children's Hospital

    Haifa, Israel

  • Schneider Children's Medical Center

    Petach Tikvah, Israel

  • American University of Beirut Medical Center

    Beirut, Lebanon

  • Makassed General Hospital

    Beirut, Lebanon

  • Rafik Hariri University Hospital

    Beirut, Lebanon

  • Saint George Hospital University Medical Center

    Beirut, Lebanon

  • University Malaya Medical Center

    Kuala Lumpur, Malaysia

  • Hospital Tuanku Jaafar

    Seremban, Negeri Sembilan, Malaysia

  • Hospital Sibu

    Sibu, Sarawak, Malaysia

  • Hospital Selayang

    Batu Caves, Selangor, Malaysia

  • Hospital Tengku Ampuan Rahimah

    Klang, Selangor, Malaysia

  • Specjalistyczny Zespół Opieki Zdrowotnej nad Matką i Dzieckiem w Poznaniu

    Poznan, Greater Poland Voivodeship, Poland

  • Nowy Szpital w Świeciu

    Gmina Świecie, Kujawy-Pomerania, Poland

  • Szpital im. Świętej Jadwigi Śląskiej w Trzebnicy

    Trzebnica, Trzebnica County, Poland

  • Kaohsiung Chang Gung Memorial Hospital

    Kaohsiung City, Taiwan

  • Mackay Memorial Hospital

    Taipei, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Taipei Municipal Wanfang Hospital

    Taipei, Taiwan

  • Linkou Chang Gung Memorial Hospital

    Taoyuan, Taiwan

  • Marmara University Faculty of Medicine

    Istanbul, Turkey (Türkiye)

  • Cukurova University Balcali Hospital

    Adana, Adana, Turkey (Türkiye)

  • Eskisehir Osmangazi University Faculty of Medicine

    Eskişehir, Eskişehir, Turkey (Türkiye)

  • Ege University Medical Faculty

    Izmir, İzmir, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.